medical guideline

SEOM Clinical Guidelines for the Treatment of Metastatic Prostate Cancer (2017)

原文:2018年 发布于 Clin Transl Oncol 20卷 第1期 57-68 浏览量:328 原文链接

作者: Spanish Society of Medical Oncology

归属分类: 所属人体系统: 生殖 | 分类: 前列腺肿瘤

关键词: Castration-resistant Prostate Cancer

指南简介

Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma.